Hemibody Irradiation

Subscribe to Selected New Research on Hemibody Irradiation

135 relevant articles (8 outcomes, 23 trials/studies) found for this Therapy

Description: Irradiation of one half or both halves of the body in the treatment of disseminated cancer or widespread metastases. It is used to treat diffuse metastases in one session as opposed to multiple fields over an extended period. The more frequent treatment modalities are upper hemibody irradiation (UHBI) or lower hemibody irradiation (LHBI). Less common is mid-body irradiation (MBI). In the treatment of both halves of the body sequentially, hemibody irradiation permits radiotherapy of the whole body with larger doses of radiation than could be accomplished with WHOLE-BODY IRRADIATION. It is sometimes called "systemic" hemibody irradiation with reference to its use in widespread cancer or metastases. (P. Rubin et al. Cancer, Vol 55, p2210, 1985)

Also Known As:

Hemi-Body Irradiation; Half Body Irradiation; Half-Body Irradiations; Hemi Body Irradiation; Hemi-Body Irradiations; Hemibody Irradiation, Sequential; Hemibody Irradiation, Systemic; Hemibody Irradiations; Hemibody Irradiations, Sequential; Hemibody Irradiations, Systemic; Irradiation, Half Body; Irradiation, Hemi-Body; Irradiation, Sequential Hemibody; Irradiation, Systemic Hemibody; Irradiations, Half-Body; Irradiations, Hemi-Body; Irradiations, Hemibody; Irradiations, Sequential Hemibody; Irradiations, Systemic Hemibody; Sequential Hemibody Irradiations; Systemic Hemibody Irradiations; Half-Body Irradiation; Irradiation, Half-Body; Irradiation, Hemibody; Sequential Hemibody Irradiation; Systemic Hemibody Irradiation

Relationship Network

Therapy Context: Research Results

Therapeutics: 5229

Radiotherapy: 176

Hemibody Irradiation: 135

Experts

1.	Li, Rui: 2 articles (12/2004 - 06/2004)
2.	Wang, Mei: 2 articles (12/2004 - 06/2004)
3.	Ning, Jun: 2 articles (12/2004 - 06/2004)
4.	Windsor, P M: 1 article (10/2008)
5.	Bashir, F A: 1 article (10/2008)
6.	Parry, J M: 1 article (10/2008)
7.	Nair, O: 1 article (02/2008)
8.	Malhotra, A: 1 article (02/2008)
9.	Senthamizhchelvan, S: 1 article (02/2008)
10.	Prabhakar, R: 1 article (02/2008)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 01/01/1992 - "A report of RTOG 8206: a phase III study of whether the addition of single dose hemibody irradiation to standard fractionated local field irradiation is more effective than local field irradiation alone in the treatment of symptomatic osseous metastases." 01/01/1992 - "Hemibody irradiation (HBI) in a single exposure is an effective and safe technique for palliation of symptoms due to widespread bony metastases (RTOG 78-10)" 12/01/1999 - "There were encouraging results from the Radiation Therapy Oncology Group (RTOG) 82-06 study suggesting that half-body irradiation (HBI) should be used earlier in the disease course to prevent the development of metastases" 08/01/1996 - "A phase I/II study to evaluate the effect of fractionated hemibody irradiation in the treatment of osseous metastases--RTOG 88-22." 12/01/2006 - "Large-field, hemi-body irradiation has been utilized for treatment of symptoms related to more widely disseminated bone metastases, but has been associated with substantial toxicity" Order ALL the reference details at left...
2.	Vomiting 12/01/1996 - "INTRODUCTION: Radiation-induced emesis is a quite frequent event when total and half body irradiation or wide fields on the pelvis, abdomen and mediastinum are employed" 11/15/1994 - "The degree of change following lower hemibody irradiation (15% incidence of emesis) in Group A was lower than upper/mid hemibody irradiation of the same group" 11/15/1994 - "The incidence of emesis was significantly different (p < 0.001) between the patients of Group A and C who received upper/mid hemibody irradiation" 11/15/1994 - "RESULTS: The incidence of radiation-induced emesis was 82% (14/17) following upper/mid hemibody irradiation and 15% (2/11) following lower hemibody irradiation in Group A; 50% (3/6) and 25% (1/4) following upper/mid and lower hemibody irradiation respectively, in Group B; and 0% (0/13) after upper/mid hemibody irradiation in Group C" 12/01/1992 - "Radiation-induced emesis can occur (1) within 2 to 3 weeks in approximately 50% of patients after conventional fractionated radiotherapy (200 cGy/fraction) to the upper abdomen, (2) acutely in more than 90% of patients receiving fractionated total body irradiation (TBI) for bone marrow transplantation, and (3) within 30 to 60 minutes in more than 80% of patients following single high-dose (> 500 cGy)/large field hemibody irradiation (HBI)" Order ALL the reference details at left...
3.	Neoplasms (Cancer) 08/01/1988 - "These pilot studies confirm the efficacy of sequential half body irradiations in systemic tumor therapy" 02/01/2008 - "Biological estimation of dose in hemi-body irradiation of cancer patients by cytogenetic analysis." 01/01/2000 - "Hemi-body irradiation (HB) with Co-60 (and a bolus) was given in cases of multiple regional tumors with large and thick infiltration of the skin to a dose of 9-12 Gy (using fractions of 1-1.5 Gy/day) which, once flattened, were boosted with whole-skin electron beam therapy (8 patients)" 07/01/1994 - "Rats bearing Walker-256, a mammary tumor, were scheduled to receive upper hemibody irradiation at 3 Gy/day for 15 times in 3 weeks if white blood cell (WBC) counts were maintained above 3,000/microliters" 10/01/1991 - "All patients (classified as IV stage) showed a progression following initial intensive therapy, including chemotherapy and, in some cases, hemi-body irradiation and surgery for their primary tumor" Order ALL the reference details at left...
4.	Multiple Myeloma 09/01/1990 - "Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study." 11/01/1996 - "We report the results of treatment of 9 patients with advanced multiple myeloma (MM) using half-body irradiation" 11/01/1996 - "Half-body irradiation in the treatment of multiple myeloma: a report of nine cases." 12/01/1995 - "Half-body irradiation in multiple myeloma." 01/01/1995 - "Double hemibody irradiation (DHBI) is an alternative treatment of stage III multiple myeloma (MM) in patients aged over 55 years" Order ALL the reference details at left...
5.	Hematologic Neoplasms (Hematological Malignancy) 06/01/2004 - "METHODS: Seventeen patients with hematological malignancies in complete remission received a high-dose chemotherapy, followed by a two-step AHBI on day 14 (12 approximately 22), upper (UHBI) and lower half body irradiation (LHBI) were sequentially given with each a single dose of 6 approximately 9 Gy at an interval of 23 (7 approximately 34) days" 12/01/2004 - "The objective of this study was to evaluate the clinical outcome of the treatment of hematologic malignancies with alternate hemibody irradiation (AHBI) combined with high-dose chemotherapy" 06/01/2004 - "Preliminary study on alternative half body irradiation in the treatment of hematological malignancies]" 12/01/2004 - "Treatment of hematologic malignancies with alternate hemibody irradiation combined with high-dose chemotherapy: a single-center experience." 06/01/2004 - "OBJECTIVE: To evaluate the curative effect of alternative half body irradiation (AHBI) in the treatment of hematological malignancies" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antiemetics
2.	Granisetron (Kytril)
3.	Ondansetron (Zofran)
4.	Teniposide (VM 26)
5.	Serotonin (5 Hydroxytryptamine)
6.	Misonidazole
7.	Interferons
8.	Carmustine (FIVB)
9.	Radioisotopes (Radionuclides)
10.	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Adjuvant Chemotherapy
4.	Palliative Care (Palliative Medicine)
5.	Salvage Therapy

Best Treatments:
Research Summary Report
on Neoplasm Metastasis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3047 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>